Trade

with

Galena Biopharma Inc
(NASDAQ: GALE)
AdChoices
1.86
-0.06
-3.13%
After Hours :
1.86
0.00
0.00%

Open

1.94

Previous Close

1.92

Volume (Avg)

1.03M (1.88M)

Day's Range

1.81-1.94

52Wk Range

1.56-7.77

Market Cap.

219.86M

Dividend Rate ( Yield )

-

Beta

1.19

Shares Outstanding

118.21M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 2.49M

    • Net Income

    • -76.68M

    • Market Cap.

    • 219.86M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,148.12

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.19

    • Forward P/E

    • -6.31

    • Price/Sales

    • 28.49

    • Price/Book Value

    • 7.76

    • Price/Cash flow

    • -4.97

      • EBITDA

      • -33.39M

      • Return on Capital %

      • -112.83

      • Return on Equity %

      • -368.68

      • Return on Assets %

      • -112.83

      • Book Value/Share

      • 0.24

      • Shares Outstanding

      • 118.21M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 6.31

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -0.29

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 82.86

            • 82.75

            • Pre-Tax Margin

            • -1,115.61

            • 39.38

            • Net Profit Margin

            • -1,148.12

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.21

              • 0.76

              • Current Ratio

              • 1.31

              • 2.92

              • Quick Ratio

              • 1.24

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 2.84

              • 2.21

              • Book Value/Share

              • 0.24

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.32

                • 277.78

                • P/E Ratio 5-Year High

                • -11.99

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.48

                • 124.82

                • Price/Sales Ratio

                • 26.67

                • 9.35

                • Price/Book Value

                • 7.27

                • 8.50

                • Price/Cash Flow Ratio

                • -4.97

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -368.68

                    (-391.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -112.83

                    (-128.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -253.24

                    (-360.50)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 3.05

                  • 1.48

                  • Asset Turnover

                  • 0.10

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -33.84M
                  Operating Margin
                  -1,360.68
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.97
                  Ownership

                  Institutional Ownership

                  16.76%

                  Top 10 Institutions

                  11.57%

                  Mutual Fund Ownership

                  9.10%

                  Float

                  99.42%

                  5% / Insider Ownership

                  1.11%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,928,127

                  • 0.00

                  • 1.63

                  • iShares Russell 2000 (AU)

                  •  

                    1,806,889

                  • -0.90

                  • 1.42

                  • Vanguard Extended Market Index Fund

                  •  

                    1,125,262

                  • 5.59

                  • 0.95

                  • iShares Russell 2000 Growth

                  •  

                    831,410

                  • -0.45

                  • 0.66

                  • Bridgeway Ultra Small Company Fund

                  •  

                    538,100

                  • 0.00

                  • 0.46

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    464,147

                  • 0.00

                  • 0.39

                  • Vanguard Instl Total Stock Market Index

                  •  

                    424,609

                  • 0.00

                  • 0.36

                  • CREF Stock

                  •  

                    365,966

                  • 3.66

                  • 0.31

                  • iShares Micro-Cap

                  •  

                    323,079

                  • 0.84

                  • 0.25

                  • Schwab Small Cap Index Fund®

                  •  

                    189,700

                  • 0.00

                  • 0.16

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    3,848,978

                  • +6.08%

                  • 3.26

                  • Vanguard Group, Inc.

                  •  

                    3,717,177

                  • +18.17%

                  • 3.15

                  • State Street Corp

                  •  

                    1,643,083

                  • -77.19%

                  • 1.39

                  • Northern Trust Investments, N.A.

                  •  

                    1,304,164

                  • -2.96%

                  • 1.10

                  • Geode Capital Management, LLC

                  •  

                    697,955

                  • +19.87%

                  • 0.59

                  • Bridgeway Capital Management, Inc

                  •  

                    538,100

                  • 0.00%

                  • 0.46

                  • TIAA-CREF Investment Management LLC

                  •  

                    468,583

                  • -44.53%

                  • 0.40

                  • BNY Mellon Asset Management Ltd.

                  •  

                    445,330

                  • +13.06%

                  • 0.38

                  • Susquehanna Financial Group, LLLP

                  •  

                    442,970

                  • +647.24%

                  • 0.37

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Galena Biopharma Inc was incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April 3, 2006 and changed its name to RXi Pharmaceuticals Corporation on November 28, 2006. On September 26, 2011, the Company changed it names fr...moreom RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. The Company is a biopharmaceutical company focused on developing and commercializing, targeted treatments that address unmet medical needs to advance cancer care. Its first commercial product, Abstral “fentanyl” Sublingual Tablets, is an important treatment option for inadequately controlled breakthrough cancer pain “BTcP”. BTcP is defined as a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequat...moreely controlled background pain. The Company has established an experienced specialty sales force in the United States, including sales management, account management, managed care and product access management, and field sales personnel. Its second immunotherapy product candidate is GALE-301, or Folate Binding Protein. GALE-301 is derived from a protein that is over-expressed (20-80 fold) in more than 90% of ovarian and endometrial cancers. GALE-301 is immunogenic and can stimulate CTLs to recognize and destroy FBP-expressing cancer cells. It is Company’s policy to protect its intellectual property rights through available means, including filing patent and prosecuting applications in the United States and other countries, protection of trade secrets, and utilizing regulatory protections such as data exclusivity and orphan drug status. The Company competes with pharmaceutical and biotechnology companies, educational institutions and research foundations. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.lessless

                  Key People

                  Dr. Mark W. Schwartz, PhD

                  President/CEO/Director

                  Sanford J. Hillsberg

                  Chairman of the Board/Director

                  Mr. Ryan Dunlap

                  CFO/Chief Accounting Officer/Controller/Secretary/Vice President

                  Dr. Brian L. Hamilton,M.D.,PhD

                  Executive VP/Chief Medical Officer

                  Dr. Rudolph Nisi,M.D.

                  Director

                  • Galena Biopharma Inc

                  • 4640 South West Macadam Avenue

                  • Portland, OR 97239

                  • USA.Map

                  • Phone: +1 855 855-4253

                  • Fax: +1 503 400-6611

                  • galenabiopharma.com

                  Incorporated

                  2006

                  Employees

                  60

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: